Sarah Romano - 01 Feb 2022 Form 4 Insider Report for KIORA PHARMACEUTICALS INC (KPRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: KPRX
Reported as of: 01 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Feb 2022, 18:06:39 UTC
Prior SEC filing: 06 Jan 2022
Next SEC filing: 11 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Sarah Romano

Key filing fact

Sarah Romano filed Form 4 for KIORA PHARMACEUTICALS INC (KPRX) on 03 Feb 2022.

Key facts

This page summarizes Sarah Romano's Form 4 filing for KIORA PHARMACEUTICALS INC (KPRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2022, 18:06.

Change

Previous filing in this sequence was filed on 06 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KPRX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 01 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.7700
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan. The Option will become exercisable as to one-third (1/3) of the shares underlying the Option on February 1, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years.